
News|Articles|November 9, 2026
- November 2026
- Volume 92
- Issue 11
Greater Than the Sum of the Parts: Pharmacists and Remote Monitoring
Author(s)Troy Trygstad, PharmD, PhD, MBA
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
Advertisement
Advertisement
Enzymes produce a product, but an enzyme paired with a coenzyme produces more of that product than the two would produce working independently. This is a classic result in biology and in nature generally, and it is also common in human production and public policy. In fancy econometric (statistical) terms, this is called an “interaction effect.” It is the incremental difference in output that comes from combining 2 or more variables, separate and apart from their individual contributions to that output. Sometimes the effect is positive, and sometimes it is negative.
Related to this article

Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.

Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.

Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.

The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.

Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.

The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.

Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Advertisement
Advertisement

